FDA / 2025
FDA grants accelerated approval to first treatment for Barth syndrome
FDA grants accelerated approval to first treatment for Barth syndrome — U.S. FDA (2025), cited in PeptideAgent's SS-31 / Elamipretide evidence record.
Open original sourceSOURCE METADATA
What this record represents.
- Publisher
- U.S. FDA
- Evidence type
- FDA
- Publication year
- 2025
- Source ID
- fda-forzinity
WHERE THIS IS CITED